Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Slides:

Advertisements

Similar presentations

Marty O’Neill II Carmen Banea

Advertisements

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Lipton JH.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review.

Soverini S et al. Proc ASH 2015;Abstract 346.

Martinelli G et al. Proc ASH 2015;Abstract 679.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 1 Key elements of cancer-related inflammation

Cortes JE et al. Proc ASCO 2010;Abstract 6502.

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 3 Monitoring clonal evolution using liquid biopsies

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Figure 3 Intracranial targeting of high-grade gliomas

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.

Luis A. Carvajal, Ulrich Steidl Cell Stem Cell

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of a patients with CUP

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Figure 3 Drug cycling with collateral sensitivity

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Mak Shu Ting (18) Yip Pui Yue (29)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 The dynamic nature of resistance mechanisms can be

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Chronic Myeloid Leukemia Challenge

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Effects of imatinib on components of the anticancer immunosurveillance system Figure 2 | Effects of imatinib on components of the anticancer immunosurveillance.

Nat. Rev. Urol. doi: /nrurol

Figure 2 Frequency and overlap of alterations

Changes in haemoglobin over the course of the treatment in a patient with chronic myeloid leukaemia who developed pure red cell aplasia secondary to imatinib.

Figure 3 Tumours secrete factors that cause systemic immunosuppression

1Kantarjian HM et al. Lancet Oncol 2011;12:

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Tyrosine kinase inhibitors

Figure 4 Molecular signalling and immunological

The Pathway to Progress Against Chronic Myelogenous Leukemia.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Presentation transcript:

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumour (GIST) Figure 1 | Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumour (GIST). a | Development of imatinib in CML. A new drug application was submitted 2 years and 9 months after the first treatment of a patient with CML, triggering the FDA approval of imatinib within 3 months of the initial application. b | Development of imatinib in GIST. Hirota and co-authors171 first discovered the somatic gain of function mutations of KIT in patients with GIST. A case report18 and the outstanding results of the phase I13 and II trials172 of imatinib led to the rapid launch of two phase III trials of this agent. The first off-target effect of imatinib was demonstrated on NK cells in 2004 (Ref. 69). PKCi, protein kinase C inhibitor; TKI, tyrosine kinase inhibitor. Kroemer, G. et al. (2016) Immunological off-target effects of imatinib Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.41